Lifecore Biomedical, Inc. (LFCR)

Lifecore Biomedical, Inc. (LFCR) Healthcare & Pipeline Overview

Lifecore Biomedical, Inc. operates as an integrated CDMO, manufacturing pharmaceutical-grade sodium hyaluronate (HA) and providing formulation and filling services. The company also has a presence in the food industry, processing and selling olive oils, wine vinegars, and avocado products, differentiating it from pure-play pharmaceutical manufacturers.

What Is the Investment Thesis for LFCR?

Lifecore Biomedical presents a mixed investment thesis. The company's expertise in HA manufacturing and formulation provides a stable revenue stream, particularly within the growing market for injectable medical products. However, the negative profit margin of -25.2% raises concerns about profitability and operational efficiency. Growth catalysts include expanding CDMO services and potential partnerships within the pharmaceutical sector. The company's beta of 0.88 suggests lower volatility compared to the broader market. Investors should closely monitor Lifecore's ability to improve its profit margins and capitalize on growth opportunities in the pharmaceutical and food segments. The company's diversification into food products adds complexity to the investment profile, requiring careful evaluation of both segments' performance and synergies.

Based on FMP financials and quantitative analysis

LFCR Key Highlights

• Market capitalization of $0.20 billion reflects its position as a smaller player in the pharmaceutical and food manufacturing industries.
• Gross margin of 31.2% indicates the profitability of its products before considering operating expenses.
• Negative profit margin of -25.2% signals potential challenges in managing costs and achieving overall profitability.
• Beta of 0.88 suggests the stock is less volatile than the overall market.
• The company operates as an integrated contract development and manufacturing organization, providing services for HA-based and non-HA based products, as well as processing and selling olive oils, wine vinegars, guacamole, and avocado food products.

Who Are LFCR's Competitors?

Who Are LFCR's Competitors?

LFCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LFCR's Key Strengths?

• Expertise in HA manufacturing and formulation
• Integrated CDMO services
• Established relationships with pharmaceutical companies and retailers
• Brand recognition in the food market

What Are LFCR's Weaknesses?

• Negative profit margin
• Dependence on a limited number of customers
• Exposure to commodity price fluctuations in the food segment
• Limited geographic diversification

What Could Drive LFCR Stock Higher?

• Potential new partnerships with pharmaceutical companies to expand CDMO services.
• Increasing demand for HA-based injectable products in ophthalmology and orthopedics.
• Expansion of private label business in the Curation Foods segment.

What Are the Key Risks for LFCR?

• Competition from other CDMOs and pharmaceutical manufacturers.
• Regulatory changes affecting the pharmaceutical and food industries.
• Negative profit margin impacting financial performance.
• Supply chain disruptions affecting the availability of raw materials.

What Are the Growth Opportunities for LFCR?

• Expansion of CDMO Services: Lifecore can leverage its expertise in HA manufacturing and formulation to expand its CDMO services to pharmaceutical companies. The global pharmaceutical CDMO market is projected to reach $108.9 billion by 2028, presenting a significant opportunity for Lifecore to increase its revenue and market share. This expansion could involve offering services for a wider range of injectable products and therapeutic areas, potentially leading to long-term contracts and recurring revenue streams.
• Strategic Partnerships: Forming strategic partnerships with pharmaceutical companies can provide Lifecore with access to new markets and technologies. These partnerships could involve co-development agreements, licensing deals, or joint ventures. By collaborating with established players in the pharmaceutical industry, Lifecore can accelerate its growth and expand its product portfolio. These partnerships can also provide access to funding and resources, enabling Lifecore to invest in research and development and expand its manufacturing capabilities.
• Product Innovation: Investing in research and development to develop new HA-based products and formulations can drive growth and differentiation. The market for HA-based products is constantly evolving, with new applications and technologies emerging. By innovating and developing new products, Lifecore can capture a larger share of the market and create a competitive advantage. This could involve developing new injectable treatments for ophthalmic, orthopedic, or other medical conditions.
• Geographic Expansion: Expanding its geographic presence can enable Lifecore to tap into new markets and customer bases. The global market for pharmaceutical products and food products is vast, with significant opportunities in emerging markets. By establishing a presence in new regions, Lifecore can diversify its revenue streams and reduce its reliance on existing markets. This could involve establishing sales offices, distribution networks, or manufacturing facilities in new countries.
• Increased Focus on Private Label Growth in Curation Foods: The Curation Foods segment can focus on expanding its private label business for olive oils, wine vinegars, guacamole, and avocado food products. The private label market is growing as retailers seek to offer high-quality products at competitive prices. By partnering with retailers to develop and manufacture private label products, Lifecore can increase its sales volume and market share. This could involve offering customized formulations, packaging, and branding options to meet the specific needs of retailers.

What Opportunities Does LFCR Have?

• Expansion of CDMO services
• Strategic partnerships with pharmaceutical companies
• Product innovation in HA-based products
• Geographic expansion into new markets

What Threats Does LFCR Face?

• Competition from other CDMOs and pharmaceutical manufacturers
• Regulatory changes affecting the pharmaceutical and food industries
• Economic downturn impacting demand for pharmaceutical and food products
• Supply chain disruptions affecting the availability of raw materials

What Are LFCR's Competitive Advantages?

• Specialized Expertise: Lifecore's expertise in HA manufacturing and formulation creates a barrier to entry for competitors.
• Integrated Services: The company's ability to offer integrated CDMO services, from technology development to manufacturing, provides a competitive advantage.
• Established Relationships: Long-standing relationships with pharmaceutical companies and retailers provide a stable customer base.
• Brand Recognition: The O, Yucatan, and Cabo Fresh brands provide a competitive advantage in the food market.

What Does LFCR Do?

Lifecore Biomedical, Inc., established in 1986 and formerly known as Landec Corporation until November 2022, is an integrated contract development and manufacturing organization (CDMO). Headquartered in Chaska, USA, Lifecore operates both domestically and internationally, serving the pharmaceutical and food industries. The company's Lifecore segment focuses on the production of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products. These products are used in various medical applications, including ophthalmic and orthopedic treatments. Lifecore also provides a range of services to its partners, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies, catering to both HA-based and non-HA based aseptically formulated and filled products. The Curation Foods segment is involved in the processing, marketing, and selling of olive oils and wine vinegars under the O brand, as well as guacamole and avocado food products under the Yucatan and Cabo Fresh brands, alongside various private label agreements. This diversified approach allows Lifecore to serve multiple markets and leverage its manufacturing expertise across different sectors.

What Products and Services Does LFCR Offer?

• Manufactures pharmaceutical-grade sodium hyaluronate (HA) in bulk form.
• Formulates and fills syringes and vials for injectable products.
• Provides technology development and analytical method development services.
• Conducts pilot and stability studies.
• Offers process validation and production of materials for clinical studies.
• Processes, markets, and sells olive oils and wine vinegars under the O brand.
• Processes, markets, and sells guacamole and avocado food products under the Yucatan and Cabo Fresh brands.
• Provides private label manufacturing for food products.

How Does LFCR Make Money?

• Contract manufacturing of HA-based and non-HA based injectable products for pharmaceutical companies.
• Sale of bulk HA to pharmaceutical companies.
• Sale of branded olive oils, wine vinegars, guacamole, and avocado food products.
• Private label manufacturing of food products for retailers.

What Industry Does LFCR Operate In?

Lifecore Biomedical operates within the specialty pharmaceutical and food manufacturing industries. The pharmaceutical CDMO market is experiencing growth driven by increased outsourcing from pharmaceutical companies seeking to reduce costs and focus on core competencies. The market for HA-based products is also expanding, fueled by demand for injectable treatments in ophthalmology and orthopedics. In the food sector, the market for olive oils, wine vinegars, and avocado products is competitive, with established players and increasing consumer demand for healthy and convenient food options. Lifecore's competitive positioning is influenced by its ability to offer integrated manufacturing services and its presence in both the pharmaceutical and food industries.

Who Are LFCR's Key Customers?

• Pharmaceutical companies seeking contract manufacturing services.
• Hospitals and clinics using HA-based injectable products.
• Retailers selling branded and private label food products.
• Consumers purchasing branded food products through retail channels.

LFCR Financials

LFCR Latest News

LFCR Analyst Consensus

LFCR MoonshotScore

What Investors Ask About Lifecore Biomedical, Inc. (LFCR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources